Affinage

GATA2

Endothelial transcription factor GATA-2 · UniProt P23769

Length
480 aa
Mass
50.5 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

GATA2 is a zinc-finger transcription factor that orchestrates the specification, generation, and survival of hematopoietic stem cells and governs differentiation programs across hematopoietic, endothelial, and reproductive tissues by binding GATA DNA motifs to activate or repress target genes in a cell-type-specific, dosage-sensitive manner (PMID:17962413, PMID:24297996, PMID:30301799). In hematopoietic stem cells it operates within a fully connected recursive triad with Fli1 and Scl/Tal1, in which each factor binds the others' enhancers (PMID:17962413), and it is genetically required for the endothelial-to-hematopoietic transition that generates HSCs as well as for their subsequent survival, two separable functions distinct from RUNX1 (PMID:24297996, PMID:29861167); threshold GATA2 levels, which pulse in individual cells during this transition, set the probability of fate establishment (PMID:29217535). GATA2 directs lineage choices by activating pro-fate targets such as HES-1 in granulocyte-macrophage progenitors (PMID:18840712) and by repressing alternative-fate genes, including Gata3 in dendritic-cell progenitors through a downstream enhancer (PMID:27259979) and GATA6 via PRC2 recruitment (PMID:29106391). Its action is dosage- and context-dependent, integrating chromatin and enhancer logic: it increases chromatin accessibility at mast-cell super-enhancers (PMID:33479210), cooperates with PU.1 and LDB1 at composite enhancers to activate Ms4a2 (PMID:31501274), and remains bound to chromatin through mitosis via its C-terminal zinc finger to bookmark RUNX1-co-enriched targets and propagate definitive hematopoietic fate (PMID:37580379). GATA2 protein abundance is controlled by cell-cycle-dependent, Cdk/cyclin-mediated phosphorylation at S/T-P motifs driving proteasomal degradation (PMID:17255359) and by MAP-kinase phosphorylation downstream of IL-3 (PMID:7876160), while its transcription is set by STAT5 (PMID:25801432), by autoregulation through GATA sites (PMID:19371385), and by repressive Setd8-mediated H4K20 monomethylation (PMID:25848090). Beyond hematopoiesis, GATA2 partners with the progesterone receptor to drive uterine PGR expression and decidualization (PMID:27783953, PMID:32335672) and controls endothelial and lymphatic development through miR-126 and miR-221 (PMID:27780851, PMID:31582413). Heterozygous zinc-finger missense mutations reduce DNA binding and transactivation, establishing GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition, with some mutants additionally sequestering PU.1 and exerting non-loss-of-function effects (PMID:21892162, PMID:28642594, PMID:30301799); GATA2 also acts as a tumor suppressor restraining PML-RARA-driven self-renewal in acute promyelocytic leukemia (PMID:34125173), and noncoding mutations that extend GATA2 expression in facial branchial motor neurons cause hereditary congenital facial paresis (PMID:37386251).

Mechanistic history

Synthesis pass · year-by-year structured walk · 34 steps
  1. 1995 High

    Established that GATA2 activity is acutely regulated by signaling, linking cytokine input to transcription-factor modification rather than treating GATA2 as a static regulator.

    Evidence In vivo phosphorylation in hematopoietic progenitors, MEK mutant epistasis in COS cells, and in vitro phosphorylation of recombinant GATA2

    PMID:7876160

    Open questions at the time
    • Direct MAP kinase phosphorylation site on GATA2 not definitively mapped
    • Functional consequence of IL-3-induced phosphorylation on target gene output unresolved
  2. 2006 Medium

    Placed GATA2 downstream of BMP4 and upstream of hemangioblast/endothelial programs, defining its role in early blood/vessel fate commitment.

    Evidence ES cell differentiation with conditional GATA2 induction and BMP4 stimulation

    PMID:17166922

    Open questions at the time
    • Direct GATA2 occupancy at Bmp4/Flk1/Scl loci not shown here
    • Temporal-window dependence not mechanistically explained
  3. 2007 High

    Showed GATA2 abundance oscillates with the cell cycle via Cdk/cyclin phosphorylation and proteasomal turnover, revealing post-translational control of a master hematopoietic factor.

    Evidence Cell-cycle synchronization, Co-IP with Cdk2/cyclinA2 and Cdk4/cyclinD1, in vitro Cdk phosphorylation, site mutagenesis, proteasome inhibition

    PMID:17255359

    Open questions at the time
    • E3 ligase mediating GATA2 degradation not identified
    • Functional output of cell-cycle-phased GATA2 levels on target genes unresolved
  4. 2007 High

    Defined the Gata2-Fli1-Scl recursive triad, providing the architecture for how HSC identity is stably maintained through mutual cross-activation.

    Evidence Reciprocal ChIP at three HSC enhancers across embryonic and ES-derived contexts with transgenic reporters

    PMID:17962413

    Open questions at the time
    • Quantitative contribution of each triad edge to HSC maintenance not dissected
    • Dynamics of circuit establishment during EHT not addressed
  5. 2008 High

    Identified HES-1 as a functional GATA2 target whose restoration rescues haploinsufficient progenitor defects, providing a concrete effector for GATA2 dosage phenotypes.

    Evidence GATA2+/- mice, ChIP at HES-1 locus, RNAi, colony/transplantation assays, HES-1 forced-expression rescue

    PMID:18840712

    Open questions at the time
    • Whether HES-1 accounts for all GMP defects unclear
    • Direct binding site within HES-1 locus not finely mapped
  6. 2009 Medium

    Demonstrated direct GATA2 positive autoregulation through defined promoter GATA sites in a non-hematopoietic (midbrain) context, generalizing self-reinforcement of GATA2 expression.

    Evidence Transgenic reporter mice with promoter-domain deletion and Gata2/Gata3 KO epistasis

    PMID:19371385

    Open questions at the time
    • Whether the same promoter domains drive hematopoietic autoregulation untested here
    • Single-lab in vivo reporter system
  7. 2011 High

    Established GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition by showing founding zinc-finger mutations reduce DNA binding and transactivation.

    Evidence Transactivation, differentiation, apoptosis, and gene expression assays on patient-derived ZF2 mutations

    PMID:21892162

    Open questions at the time
    • In vivo leukemogenic mechanism not modeled in this study
    • Cell-of-origin and second-hit requirements unaddressed
  8. 2013 High

    Genetically separated GATA2's role in HSC generation during EHT from its requirement in HSC survival, refining when and where GATA2 acts and distinguishing it from RUNX1.

    Evidence Vec-Cre and Vav-Cre conditional Gata2 deletion with LT-repopulation and aortic cluster analysis

    PMID:24297996

    Open questions at the time
    • Survival-stage target genes not defined
    • Molecular distinction from RUNX1 at the target level unresolved
  9. 2013 Medium

    Extended GATA2 function beyond hematopoiesis by showing it forms complexes with LMO2 to activate NRP2 and drive angiogenesis/lymphangiogenesis.

    Evidence siRNA/overexpression, sprouting assays, NRP2 promoter analysis and rescue in endothelial cells

    PMID:23892628

    Open questions at the time
    • Direct GATA2-LMO2 physical interaction not biochemically resolved here
    • Partial NRP2 rescue implies additional effectors
  10. 2013 Medium

    Revealed GATA2 as a context-dependent repressor recruiting PRC2 to silence GATA6, expanding its mechanistic repertoire to Polycomb-mediated repression.

    Evidence ChIP for GATA2 and PRC2 at GATA6 locus with KD/OE and bisulfite analysis in gastric cancer cells

    PMID:29106391

    Open questions at the time
    • Direct GATA2-PRC2 contact not demonstrated
    • Single cancer-cell context
  11. 2014 High

    Identified GATA2 as a driver of androgen receptor expression and a chromatin co-factor with AR/FOXA1 in prostate cancer, defining an oncogenic transcriptional role.

    Evidence ChIP co-occupancy, Co-IP, coactivator recruitment, KD/OE in prostate cancer cells with patient correlation

    PMID:25489091

    Open questions at the time
    • Direct vs. indirect coactivator bridging not separated
    • Generalizability beyond prostate lineage untested
  12. 2014 Medium

    Showed GATA2 physically partners with Etv2 via GATA/Ets domains to co-activate shared endothelial/hematopoietic targets, providing a protein-level cooperativity mechanism.

    Evidence Reciprocal Co-IP, domain-mapping, embryoid-body differentiation, ChIP at Spi1 promoter

    PMID:24583263

    Open questions at the time
    • Genome-wide co-occupancy not assessed
    • Functional necessity of the interaction in vivo not tested
  13. 2015 High

    Placed GATA2 downstream of STAT5 as a direct transcriptional target sufficient to drive basophil/mast-cell fate, connecting cytokine signaling to GATA2-driven differentiation.

    Evidence STAT5 ChIP at Gata2 locus and Gata2 overexpression rescue in Stat5-deficient cells

    PMID:25801432

    Open questions at the time
    • Other STAT5-independent inputs to Gata2 not delineated
    • Lineage breadth of this pathway beyond basophil/mast cell unclear
  14. 2015 High

    Defined repressive epigenetic control of the Gata2 locus by Setd8/H4K20me1 during erythroid maturation, showing Gata2 silencing is required for differentiation.

    Evidence Setd8 knockdown, ChIP for occupancy and histone marks at Gata2 locus, Gata2 KD rescue in erythroblasts

    PMID:25848090

    Open questions at the time
    • How Setd8 is targeted to the Gata2 locus unknown
    • Whether this mechanism operates in HSCs untested
  15. 2016 High

    Established GATA2 as a uterine regulator activating PGR and progesterone signaling, defining a reproductive function essential for implantation and decidualization.

    Evidence Uterine conditional Gata2 KO with ChIP-seq at Pgr and RNA-seq, implantation/decidualization phenotyping

    PMID:27783953

    Open questions at the time
    • Upstream regulators of uterine GATA2 not defined
    • GATA2-PGR physical interaction not addressed here
  16. 2016 High

    Showed GATA2 controls vascular integrity through opposing regulation of miR-126 and miR-221, including DNA-methylation-mediated silencing, broadening its endothelial effector network.

    Evidence Endothelial KD/OE, ChIP, luciferase, bisulfite sequencing, and in vivo carotid-injury miR-126 rescue

    PMID:27780851

    Open questions at the time
    • Mechanism by which GATA2 directs miR-221 promoter methylation unclear
    • Relative contribution of each miRNA arm in vivo not partitioned
  17. 2016 High

    Demonstrated GATA2 represses Gata3 via a long-range enhancer to enforce myeloid over lymphoid identity in dendritic-cell progenitors.

    Evidence Conditional/haploinsufficient mice, in vitro DC generation, reporter assays with GATA-site mutagenesis at Gata3 +190

    PMID:27259979

    Open questions at the time
    • Co-repressors mediating Gata3 silencing not identified
    • Direct vs. indirect myeloid gene activation not fully separated
  18. 2017 High

    Refined the GATA2 mutation model by showing ZF2 mutants not only lose DNA binding but can gain PU.1 sequestration, indicating effects beyond simple haploinsufficiency.

    Evidence DNA-binding, transactivation, Co-IP with PU.1, colony and cell-fate assays on multiple mutants

    PMID:28642594

    Open questions at the time
    • In vivo relevance of enhanced PU.1 binding untested
    • Allele-specific clinical correlation not established
  19. 2017 Medium

    Showed GATA2 is required for AR-driven SEMA3C activation, reinforcing its role as an obligate co-factor in androgen-responsive transcription.

    Evidence ChIP for GATA2/AR at SEMA3C, GATA2 KD, androgen stimulation, luciferase assays in LNCaP

    PMID:28038451

    Open questions at the time
    • Mechanism of FOXA1 antagonism not resolved
    • Single-cell-line context
  20. 2018 High

    Demonstrated that disease-associated N-finger mutations reduce chromatin occupancy yet can promote myeloid differentiation, showing GATA2 pathogenesis is not strictly loss-of-function.

    Evidence Genetic complementation in -77 enhancer-mutant myeloid progenitors with occupancy and differentiation readouts

    PMID:30301799

    Open questions at the time
    • Mechanism of myeloid-promoting gain-of-function unclear
    • Relationship to leukemic transformation not directly tested
  21. 2019 High

    Dissected enhancer-specific functions, showing the +9.5 Ets motif is dispensable for steady-state but essential for stress regeneration, separating developmental from regenerative GATA2 activity.

    Evidence Mouse knockin of +9.5 Ets-motif mutations with steady-state vs. stress hematopoiesis assays

    PMID:30620726

    Open questions at the time
    • Stress-specific transcription factors acting at +9.5 not identified
    • Molecular basis of regeneration-selective requirement unresolved
  22. 2019 High

    Defined composite enhancer logic in mast cells, showing GATA2 and PU.1 cooperate with LDB1 at a downstream enhancer essential for Ms4a2, with PU.1 supporting GATA2 binding.

    Evidence ChIP-seq, siRNA, genome-editing deletion of +10.4-kbp enhancer, chromatin looping

    PMID:31501274

    Open questions at the time
    • Hierarchy of GATA2/PU.1/LDB1 assembly not fully ordered
    • Generality across mast-cell genes untested
  23. 2019 High

    Showed GATA2 governs lymphatic valve morphogenesis through miR-126 control of junctional molecules, linking GATA2 to endothelial barrier architecture.

    Evidence Conditional GATA2 KO mouse and HLEC siRNA with miR-126 overexpression rescue and junction immunostaining

    PMID:31582413

    Open questions at the time
    • Direct GATA2 occupancy at junction genes vs. miR-126-mediated effect not fully separated
    • Valve-specific co-factors unidentified
  24. 2019 Medium

    Modeled GATA2 hypomorphism as causing CMML-like disease with myeloid bias and cytokine-receptor upregulation, connecting reduced dosage to specific malignant phenotypes.

    Evidence Gata2 hypomorphic neocassette mice with transplantation, expression analysis, LPS challenge

    PMID:30710465

    Open questions at the time
    • Direct GATA2 regulation of CSF1R/IL6R not demonstrated
    • Single-lab model
  25. 2019 High

    Pinpointed the precise developmental window of GATA2 requirement to the EHT step of hemogenic endothelium, showing it is dispensable for HE specification and diversification.

    Evidence GATA2 KO hESC lines with conditional/forced expression and hematopoietic differentiation assays

    PMID:29861167

    Open questions at the time
    • Targets executing the EHT step not catalogued
    • Why forced GATA2 cannot reprogram non-HE unexplained
  26. 2020 High

    Used multiomics to show the -77 enhancer coordinates both pro-fate and innate-immunity anti-fate circuits, reframing GATA2 dosage as balancing opposing programs in single progenitors.

    Evidence Murine -77 enhancer deletion with single-cell multiomics and differentiation assays

    PMID:32736380

    Open questions at the time
    • Identity of the fate-suppressing innate immunity effectors incomplete
    • Mechanism linking GATA2 level to immunity program off-switch unresolved
  27. 2020 Medium

    Showed conserved enhancer-driven Gata2 autoactivation in zebrafish hemogenic endothelium feeds into runx1 and Notch circuitry, generalizing GATA2 positive autoregulation in blood development.

    Evidence CRISPR i4 enhancer deletion with downstream runx1/gata2b expression and Notch analysis

    PMID:32054973

    Open questions at the time
    • Direct GATA2 binding at i4 not shown here
    • Mapping to mammalian enhancers uncertain
  28. 2020 Medium

    Established genome-wide GATA2-PGR co-occupancy as the basis of decidualization gene regulation, deepening the GATA2 reproductive mechanism.

    Evidence GATA2 ChIP-seq and RNA-seq integrated with PGR ChIP-seq in human endometrial stromal cells

    PMID:32335672

    Open questions at the time
    • Direct GATA2-PGR physical interaction not tested
    • Causality of co-binding vs. sequential binding unresolved
  29. 2021 High

    Showed GATA2 establishes chromatin accessibility at mast-cell super-enhancers and primes antigen-responsive loci, framing it as a determinant of enhancer landscape and identity.

    Evidence GATA2 KO mast cells with ATAC-seq, ChIP-seq, and RNA-seq

    PMID:33479210

    Open questions at the time
    • Whether GATA2 acts as a pioneer factor at these sites not directly demonstrated
    • Order relative to other identity factors unresolved
  30. 2021 High

    Defined GATA2 as a tumor suppressor restraining PML-RARA-driven self-renewal, with the R362G allele confirmed as loss-of-function in APL.

    Evidence CRISPR biallelic Gata2 KO, serial replating, mouse leukemia penetrance/latency, WT and mutant addback

    PMID:34125173

    Open questions at the time
    • Target genes mediating self-renewal suppression not identified
    • Interaction with PML-RARA at chromatin not characterized
  31. 2022 High

    Placed GATA2 downstream of HMGA1 as a target whose re-expression partially rescues leukemogenesis, linking it to a chromatin-accessibility regulatory axis in MPN.

    Evidence CRISPR/shRNA, RNA-seq, HMGA1 ChIP-seq at +9.5 GATA2 enhancer, accessibility assays, GATA2 rescue

    PMID:35286385

    Open questions at the time
    • Why GATA2 re-expression only partially rescues unresolved
    • Context-dependence (tumor-suppressor vs. oncogenic) of GATA2 in myeloid disease not reconciled
  32. 2023 High

    Demonstrated GATA2 mitotic bookmarking via the C-terminal zinc finger maintains definitive hematopoietic fate, providing a mechanism for heritable transcriptional memory through cell division.

    Evidence Live imaging, GATA2-cyclinB1 degron knockin mouse, mitotic vs. interphase ChIP, ZF domain deletion, multiomics

    PMID:37580379

    Open questions at the time
    • How bookmarked targets are reactivated post-mitosis not detailed
    • Functional role of RUNX1 co-enrichment at bookmarked sites untested
  33. 2023 High

    Linked noncoding GATA2 regulatory mutations that extend its expression in facial motor neurons to hereditary congenital facial paresis, establishing a gain-of-expression neurodevelopmental disease mechanism.

    Evidence Human genetic mapping, humanized HCFP1 mouse, NR2F1 binding assays, FBMN reporter assays, Gata3 KO rescue

    PMID:37386251

    Open questions at the time
    • Full set of GATA2 targets driving FBMN-to-IEE fate shift unresolved
    • Generalizability of silencer/enhancer logic to other GATA2-dependent tissues unclear
  34. 2025 High

    Identified RASSF4 as a GATA2 target that dampens p53-mediated apoptosis, providing a mechanism by which GATA2 levels modulate chemoresistance in AML.

    Evidence ChIP-seq, RNA-seq, CRISPR GATA2 deletion, Rassf4 KD/OE, doxorubicin and nutlin-3 assays, patient data

    PMID:39841459

    Open questions at the time
    • Direct RASSF4-MDM2-p53 biochemical link not shown here
    • Therapeutic exploitability across GATA2-mutant subtypes untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How GATA2 dosage and the same DNA-binding activity are reconciled across opposing roles — pro-fate activator vs. anti-fate repressor, tumor suppressor vs. oncogenic AR co-factor — remains unresolved at the level of context-defining co-factors and chromatin state.
  • No unified model linking GATA2 partner identity to activator vs. repressor output
  • E3 ligase and full post-translational control network incomplete
  • Determinants of tissue-specific enhancer selection not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 4
Localization
GO:0000228 nuclear chromosome 2 GO:0005634 nucleus 2
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1266738 Developmental Biology 4 R-HSA-4839726 Chromatin organization 4 R-HSA-1643685 Disease 3
Partners
ARETV2FLI1FOXA1LMO2PGRPU.1TAL1
Complex memberships
Gata2-Fli1-Scl HSC triadPRC2 (recruited by GATA2 at GATA6 locus)

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 Heterozygous GATA2 missense mutations (p.Thr354Met, p.Thr355del) within the second zinc finger domain reduce DNA-binding affinity and transactivation of target genes, and differentially affect cellular differentiation and apoptosis, establishing haploinsufficiency as a mechanism of MDS-AML predisposition. Functional transactivation assays, cellular differentiation assays, apoptosis assays, global gene expression profiling of patient-derived mutations Nature genetics High 21892162
1995 GATA2 is phosphorylated in hematopoietic progenitor cells; IL-3 stimulation enhances GATA2 phosphorylation within 5 minutes via the MAP kinase pathway, as demonstrated by constitutively activating and interfering MAP kinase kinase mutants; in vitro phosphorylation experiments raise the possibility that MAP kinase directly phosphorylates GATA2. In vivo phosphorylation assays in hematopoietic progenitors, genetic manipulation of MAP kinase pathway in COS cells (activating/interfering MEK mutants), in vitro phosphorylation with recombinant GATA2 The Journal of biological chemistry High 7876160
2007 GATA2 expression oscillates during the cell cycle in hematopoietic cells (high in S phase, low in G1/S and M phase) due to proteasome-dependent degradation regulated by phosphorylation at Cdk-consensus (S/T-P) motifs; GATA2 physically interacts with Cdk2/cyclin A2 and Cdk4/cyclin D1 complexes and is phosphorylated by these in vitro; mutations at phosphorylation motifs alter cell-cycle-specific GFP-GATA2 expression profiles. Cell-cycle synchronization, GFP-GATA2 fusion protein imaging, immunoprecipitation/immunoblotting for Cdk interactions, in vitro phosphorylation by Cdk/cyclin, phosphorylation-site mutagenesis, proteasome inhibition Blood High 17255359
2007 Gata2, Fli1, and Scl/Tal1 form a fully connected recursive gene-regulatory circuit (triad) in hematopoietic stem cells; each of these transcription factors binds the enhancers of the other two (Gata2-3, Fli1+12, Scl+19) in embryonic dorsal aorta, fetal liver, and ES cell-derived hemangioblast equivalents. Chromatin immunoprecipitation (ChIP) at multiple HSC enhancers, enhancer-reporter transgenic mice, cis-element motif analysis Proceedings of the National Academy of Sciences of the United States of America High 17962413
2006 GATA2 is a direct transcriptional target of BMP4 in hemangioblast development; enforced GATA2 expression upregulates Bmp4, Flk1, and Scl; conditional GATA2 induction increases hemangioblast generation and endothelial cell production and confers a proliferative signal to primitive erythroid progenitors in a temporal-sensitive manner. ES cell differentiation system, conditional GATA2 induction, gene expression analysis, BMP4 stimulation experiments Development (Cambridge, England) Medium 17166922
2008 GATA2 regulates granulocyte-macrophage progenitor (GMP) function through transcriptional activation of HES-1; GATA2 binds the HES-1 locus in myeloid progenitor cells, and enforced HES-1 expression in GATA2-heterozygous GMPs rescues the functional defect caused by GATA2 haploinsufficiency. GATA2+/- mouse analysis, RNA interference knockdown, colony-forming assays, competitive transplantation, ChIP at HES-1 locus, HES-1 forced expression rescue Blood High 18840712
2013 GATA2 function is essential for endothelial-to-hematopoietic transition (EHT) during HSC generation from VE-Cadherin-expressing endothelial cells, and is also required for HSC survival after generation in Vav-expressing hematopoietic cells; these two roles are genetically separable and distinct from RUNX1 function. Conditional Gata2 deletion using Vec-Cre (endothelial) and Vav-Cre (hematopoietic) lineage-specific mouse models, long-term repopulation assays, intra-aortic cluster analysis The Journal of experimental medicine High 24297996
2012 GATA2 loss in VE-enhancer-expressing endothelial cells causes anemia via HSC loss in fetal liver and defective lymphatic vascular development; the VE enhancer also regulates GATA2 expression in definitive fetal liver and adult bone marrow HSCs. Tamoxifen-inducible Cre transgenic mice (Gata2 VECre), in vitro colony-forming assays, immunophenotyping, in vivo long-term competitive repopulation, embryo morphology analysis The Journal of clinical investigation High 22996665
2014 GATA2 directly promotes expression of both full-length and splice-variant androgen receptor (AR) in prostate cancer; GATA2 co-localizes with AR and FOXA1 on chromatin and enhances recruitment of steroid receptor coactivators (SRC) and formation of the transcriptional holocomplex; AR/androgen negatively regulates GATA2 in a feedback loop. ChIP, gene expression profiling, Co-IP, knockdown/overexpression experiments in prostate cancer cell lines, patient specimen correlation Proceedings of the National Academy of Sciences of the United States of America High 25489091
2013 GATA2 and LMO2 form transcriptional complexes in endothelial and lymphatic endothelial cells and cooperatively regulate VEGF-induced angiogenesis and lymphangiogenesis by directly activating neuropilin-2 (NRP2) gene expression at the promoter level; NRP2 overexpression partially rescues impaired angiogenic sprouting caused by GATA2/LMO2 knockdown. siRNA knockdown, lentiviral overexpression, angiogenic sprouting assays, NRP2 promoter analysis, NRP2 rescue experiments in endothelial and lymphatic endothelial cells Angiogenesis Medium 23892628
2014 Etv2 and Gata2 physically interact in vitro and in vivo; the protein-protein interaction is mediated by the Ets and GATA domains; co-expression of Gata2 augments Etv2 activity in promoting endothelial and hematopoietic lineage differentiation; Etv2 and Gata2 both bind the Spi1 promoter in vitro and in vivo. Co-immunoprecipitation in vitro and in vivo, embryoid body differentiation system, ChIP at Spi1 promoter, domain-deletion interaction mapping Developmental biology Medium 24583263
2015 STAT5 directly binds the Gata2 promoter and an intronic region, transcriptionally activating Gata2; overexpression of Gata2 alone is sufficient to direct basophil and mast cell differentiation in the absence of Stat5, establishing GATA2 as a downstream effector in the STAT5-GATA2 pathway for basophil and mast cell differentiation. ChIP of STAT5 at Gata2 locus, Gata2 overexpression in Stat5-deficient cells, conditional knockout mice, differentiation assays Journal of immunology High 25801432
2015 GATA2 regulates erythroid maturation through transcriptional repression of Gata2 by histone methyltransferase Setd8 (which monomethylates H4K20); Setd8 occupies regulatory elements in the Gata2 locus, and Setd8 knockdown leads to loss of H4K20me1 and gain of H4 acetylation at the Gata2 1S promoter, increasing GATA2 expression; Gata2 knockdown rescues maturation impairments caused by Setd8 disruption. Stable Setd8 knockdown in erythroblasts, global gene expression, ChIP for Setd8 occupancy and histone marks at Gata2 locus, Gata2 knockdown rescue experiments Molecular and cellular biology High 25848090
2016 Uterine GATA2 directly occupies and promotes expression of the progesterone receptor (PGR) gene and co-regulates downstream progesterone-responsive genes in conjunction with PGR; uterine-specific Gata2 ablation causes infertility via impaired embryo implantation, decidualization failure, reduced PGR expression, and attenuated progesterone signaling. Uterine-specific conditional Gata2 knockout mice, genome-wide ChIP-seq (GATA2 occupancy at Pgr locus), RNA-seq, implantation and decidualization phenotyping Cell reports High 27783953
2016 GATA2 deficiency in endothelial cells causes vascular abnormalities through regulation of miR-126 (pro-angiogenic) and miR-221 (anti-angiogenic); GATA2 transcriptionally activates miR-126 (which targets SPRED1 and FOXO3a) and suppresses miR-221 expression via DNA methylation of the miR-221 promoter CpG island; miR-221 silencing or miR-126 supplementation reverses the GATA2-deficient vascular phenotype. Endothelial siRNA knockdown and lentiviral overexpression, ChIP, luciferase promoter assays, bisulfite sequencing, proteome profiler, luciferase reporter gene assays, carotid injury mouse model with nanoparticle miR-126 delivery Circulation High 27780851
2016 GATA2 is required for DC differentiation via the myeloid pathway; GATA2 binds an enhancer element 190-kb downstream of the Gata3 locus and represses Gata3 expression in DC progenitors; loss of GATA2 leads to reduced myeloid gene expression (including mafb) and increased T-lymphocyte gene expression (including Gata3 and Tcf7) in DC progenitors. Gata2 conditional knockout and haploinsufficient mice, in vitro DC generation from progenitors, expression profiling, luciferase reporter assay with Gata3 +190 enhancer and GATA sequence deletion Blood High 27259979
2017 GATA2 missense mutations in zinc finger 2 (gT354M, gR396Q, gR398W, gC373R) display reduced DNA-binding affinity and transactivation compared to wild-type; two mutants (gT354M and gC373R) bind PU.1 more strongly than wild-type GATA2, potentially perturbing differentiation through PU.1 sequestration; all mutants except sL359V fail to suppress colony formation and some skew cell fate to granulocytes. DNA-binding affinity assays, transactivation reporter assays, Co-immunoprecipitation with PU.1, colony formation assays, cell fate analysis Leukemia High 28642594
2018 GATA2 N-finger (amino-terminal zinc finger) mutations decrease GATA2 chromatin occupancy and attenuate target gene regulation; in a genetic complementation assay in myeloid progenitors, GATA2 disease mutants fail to induce erythroid differentiation but unexpectedly promote myeloid differentiation and proliferation, indicating GATA2 mutations are not strictly loss-of-function and that haploinsufficiency does not fully explain pathogenesis. Genetic complementation assay in Gata2 -77 enhancer-mutant mouse myeloid progenitors, chromatin occupancy assays, erythroid and myeloid differentiation assays Proceedings of the National Academy of Sciences of the United States of America High 30301799
2019 A single-nucleotide mutation in the Ets motif of the GATA2 +9.5 intronic enhancer does not impair steady-state hematopoiesis but abrogates stem/progenitor cell regeneration following hematopoietic stress, revealing that a disease predisposition mutation can selectively inactivate enhancer regenerative activity while sparing developmental activity. Mouse knockin models of +9.5 enhancer Ets motif mutations, steady-state hematopoiesis analysis, stress-induced hematopoietic regeneration assays The Journal of clinical investigation High 30620726
2019 GATA2 and PU.1 cooperatively activate Ms4a2 (FcεRIβ) gene expression in mast cells through distinct mechanisms: GATA2 exclusively binds the proximal -60-bp promoter region in a mast cell-specific manner, while both GATA2 and PU.1 share binding at a +10.4-kbp downstream enhancer with LDB1; PU.1 ablation reduces GATA2 binding at both sites; deletion of the +10.4-kbp region by genome editing completely abolishes Ms4a2 expression. ChIP-seq, siRNA knockdown, genome editing (deletion of +10.4-kbp enhancer), chromatin looping analysis, mast cell gene expression assays Molecular and cellular biology High 31501274
2019 GATA2 controls lymphatic vascular development and lymphovenous valve morphogenesis by regulating expression of miR-126, which in turn controls cell junction molecules VE-cadherin and claudin 5; miR-126 overexpression in GATA2-depleted lymphatic endothelial cells significantly rescues cell junction defects. Conditional GATA2 knockout mouse, primary human lymphatic endothelial cell (HLEC) siRNA knockdown, miR-126 overexpression rescue, junction molecule immunostaining Development (Cambridge, England) High 31582413
2020 GATA2 deletion of the murine -77 enhancer (human equivalent causes leukemia) downregulates GATA2 and blocks progenitor differentiation into erythrocytes, megakaryocytes, basophils, and granulocytes (but not macrophages); multiomics and single-cell analyses show the enhancer coordinates both pro-fate and anti-fate (innate immunity-linked) circuitry in individual progenitor cells; increasing GATA2 via the enhancer both promotes fate and abrogates a fate-suppressing innate immunity program. Murine Gata2 -77 enhancer deletion, multiomics (transcriptomics + chromatin), single-cell analysis, progenitor differentiation assays The Journal of experimental medicine High 32736380
2020 GATA2 directly activates CGA transcription; secreted CGA binds EGFR and activates EGFR signaling conferring chemoresistance; EGFR signaling in turn induces GATA2 expression and phosphorylation, forming a positive feedback circuit; N-glycosylation of CGA at Asn52 and Asn78 is required for CGA stability, secretion, and EGFR interaction. Secretome screening, conditioned media experiments, EGFR signaling assays, GATA2 overexpression/knockdown, mutagenesis of CGA N-glycosylation sites, ChIP for GATA2 at CGA promoter, microRNA target assays The Journal of clinical investigation Medium 35289315
2021 GATA2 promotes chromatin accessibility at super-enhancers of mast cell identity genes and primes both typical and super-enhancers at genes that respond to antigenic stimulation; GATA2-bound sites are several-fold denser at super-enhancers than at typical enhancers in mast cells. GATA2 knockout mast cells, ATAC-seq, ChIP-seq for GATA2 binding at super-enhancers and typical enhancers, RNA-seq Nature communications High 33479210
2022 HMGA1 transactivates GATA2 through sequences near the +9.5 developmental enhancer, increasing chromatin accessibility and recruiting active histone marks; silencing GATA2 recapitulates most phenotypes of HMGA1 depletion in MPN cells, and GATA2 re-expression partially rescues leukemogenesis after HMGA1 loss. CRISPR/Cas9 disruption, shRNA knockdown, RNA-seq, ChIP-seq (HMGA1 occupancy at +9.5 GATA2 enhancer), chromatin accessibility assays, GATA2 rescue experiments Blood High 35286385
2023 GATA2 undergoes mitotic bookmarking via C-terminal zinc finger-mediated DNA binding, remaining bound to chromatin throughout mitosis in contrast to GFI1B and FOS; it bookmarks a subset of interphase targets co-enriched for RUNX1; conditional GATA2 degradation at mitotic exit in mice (cyclin B1 degradation domain knockin) abolishes definitive haematopoiesis at AGM, placenta, and fetal liver without impairing yolk sac haematopoiesis. Live-cell imaging, GATA2-cyclin B1 degradation domain knockin mouse model, ChIP during mitosis vs. interphase, domain-deletion experiments (C-terminal zinc finger), multiomics Nature communications High 37580379
2009 GATA2 positively autoregulates its own transcription in the mouse midbrain through two discrete promoter domains (5H at -3.0 kbp and 2H at -1.9 kbp upstream of TSS) that both contain GATA factor binding sites; GATA2 (but not GATA3) is essential for Gata2 gene expression in the midbrain. Transgenic reporter mice, in vivo deletion analysis of promoter domains, Gata2/Gata3 knockout analyses, domain-specific reporter constructs Genes to cells Medium 19371385
2017 GATA2 directly binds to the SEMA3C androgen response element in a GATA2-dependent manner, and AR-mediated transcriptional activation of SEMA3C requires GATA2; FOXA1 is a negative regulator of SEMA3C expression in the same context. ChIP for GATA2 and AR at SEMA3C locus, GATA2 knockdown in LNCaP cells, androgen stimulation experiments, luciferase reporter assays Oncotarget Medium 28038451
2013 GATA2 directly represses GATA6 expression in gastric cancer cells by recruiting the PRC2 complex to the GATA6 locus; disruption of GATA2 expression impairs PRC2 recruitment and results in GATA6 upregulation; GATA2 and PRC2 complexes are enriched within the GATA6 locus as demonstrated by ChIP. ChIP for GATA2 and PRC2 at GATA6 locus, GATA2 overexpression and knockdown, ectopic expression, bisulfite methylation analysis Oncogene Medium 29106391
2020 GATA2 transcriptionally activates the Gata2 locus in endothelial haemogenic cells partly through the i4 pan-endothelial enhancer in zebrafish; deletion of the i4 enhancer reduces Gata2a, which in turn reduces runx1 and gata2b expression in hemogenic endothelium, and recovery is mediated by Notch signalling. CRISPR/Cas9 deletion of i4 enhancer in zebrafish, expression analysis of runx1/gata2b, Notch pathway analysis, adult hematopoiesis phenotyping Communications biology Medium 32054973
2017 In vivo time-lapse imaging reveals that Gata2 reporter expression shows rapid pulsatile level changes in individual cells undergoing endothelial-to-hematopoietic transition (EHT) in the aorta; Gata2 haploinsufficient cells exhibit fewer transitions and reduced hematopoietic potential, suggesting threshold levels of Gata2 control fate establishment. Gata2Venus knock-in reporter mouse, time-lapse live imaging of aortic cells during EHT, single-cell quantitative fluorescence analysis, comparison with Gata2 heterozygous aortic cells The Journal of experimental medicine High 29217535
2025 GATA2 transcriptionally regulates RASSF4, a modulator of the p53 inhibitor MDM2, thereby dampening p53-mediated apoptosis; GATA2 deletion results in more robust p53 induction after doxorubicin exposure; RASSF4 and GATA2 are anticorrelated in AML; knockdown of Rassf4 in Gata2-low cells confers doxorubicin resistance; overexpression of Rassf4 sensitizes Gata2-high cells. ChIP-seq, RNA-seq, GATA2 deletion (CRISPR/Cas9), Rassf4 knockdown and overexpression, doxorubicin sensitivity assays, nutlin-3 experiments, single-cell and bulk patient expression data Blood High 39841459
2013 Progesterone receptor B (PGR-B) drives Ednra gene activation through one of six progesterone response elements (PRE6) in a conserved upstream region; GATA2 activity at a GATA2 site in the same region is required for the progesterone response, and GATA2 synergizes with PGR-B to enhance Ednra expression. In vivo pregnancy/progesterone experiments, promoter deletion analysis, luciferase reporter assays, GATA2 site mutagenesis Molecular endocrinology Medium 23592430
2019 GATA2 is not required for VE-cadherin+CD43-CD73- hemogenic endothelium (HE) specification or HE diversification into DLL4+ arterial and DLL4- non-arterial lineages, but is primarily required for HE to undergo endothelial-to-hematopoietic transition (EHT); forced GATA2 expression in non-HE failed to induce blood formation. GATA2 knockout hESC lines with conditional GATA2 expression (iG2-/- hESCs), hematopoietic differentiation assays, flow cytometry for HE and hematopoietic progenitor phenotypes Stem cell reports High 29861167
2021 GATA2 functions as a tumor suppressor in acute promyelocytic leukemia (APL); biallelic Gata2 knockout by CRISPR/Cas9 increases serial replating efficiency of PML-RARA-expressing progenitors, increases APL penetrance, and decreases latency; restoration of Gata2 suppresses PML-RARA-driven aberrant self-renewal; a mutant GATA2-R362G (associated with APL/AML) minimally suppresses PML-RARA-induced self-renewal, indicating it is a loss-of-function mutation. CRISPR/Cas9 Gata2 biallelic knockout, serial replating assays, mouse leukemia model (penetrance/latency), Gata2 restoration experiments, mutant addback experiments Blood High 34125173
2019 GATA2 hypomorphism (reduced Gata2 expression by neocassette insertion) in mice induces chronic myelomonocytic leukemia-like disease characterized by granulomonocytosis, trilineage dysplasia, impaired HSC reconstitution activity, and myeloid lineage-biased proliferation; GATA2 hypomorphic progenitors show increased expression of CSF1R and IL6R, correlating with hypersensitive granulomonocytic proliferation. Gata2 hypomorphic mouse model (neocassette knockin), competitive transplantation, gene expression analysis of myeloid progenitors, LPS challenge experiments Cancer science Medium 30710465
2023 Noncoding heterozygous duplications within a neuron-specific GATA2 regulatory region (including two enhancers and one silencer) or SNVs within the silencer cause hereditary congenital facial paresis (HCFP1) by extending GATA2 expression; some SNVs impair NR2F1 binding to the silencer in vitro and in vivo, attenuating enhancer reporter expression in facial branchial motor neurons; a humanized HCFP1 mouse model confirms that extended Gata2 expression favors IEE over FBMN formation, rescued by conditional loss of Gata3. Human genetic mapping, humanized HCFP1 knockin mouse model, in vitro and in vivo NR2F1 binding assays, enhancer reporter assays in FBMNs, Gata3 conditional knockout rescue Nature genetics High 37386251
2020 GATA2 and progesterone receptor (PGR) co-occupy and co-regulate genes during human endometrial stromal cell decidualization; the PGR motif is highly enriched at GATA2 binding regions surrounding upregulated genes; GATA2 binding is enhanced at PGR-binding regions during decidualization, with co-regulation of WNT activation and stem cell differentiation pathways. RNA-seq, ChIP-seq (GATA2 cistrome in decidualization), integration with mined PGR ChIP-seq, pathway analysis Endocrinology Medium 32335672
2019 GATA2 is required for GATA2 target gene GATA2 own transcription in the midbrain via GATA binding sites in the promoter; Gata2 promotes definitive haematopoiesis by directly binding GATA motifs within target gene regulatory regions. Referenced in context of broader auto-regulatory mechanism IUBMB life Low 31675473
2004 Zebrafish Pur alpha functions as a repressor and Sp8 as an activator of neural gata2 expression during embryogenesis, as demonstrated by knockdown and ectopic expression experiments. Morpholino knockdown of Pur alpha and Sp8 in zebrafish, ectopic expression, gata2 neural expression analysis Developmental biology Medium 15464585
2021 GATA2 regulates constitutive PD-L2 expression in brain tumors; GATA2 is sufficient to drive both PD-L1 and PD-L2 expression and is necessary for PD-L2 expression, as demonstrated by characterization of novel cis-regulatory regions in CD274 and PDCD1LG2 using luciferase assays and perturbation of GATA2. Luciferase assays with CD274/PDCD1LG2 cis-regulatory regions, GATA2 overexpression and knockdown in brain tumor cell lines and BTICs, flow cytometry for PD-L1/PD-L2 Scientific reports Medium 32493985

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature genetics 471 21892162
2015 Haematopoietic and immune defects associated with GATA2 mutation. British journal of haematology 198 25707267
2013 Gata2 is required for HSC generation and survival. The Journal of experimental medicine 197 24297996
2007 Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proceedings of the National Academy of Sciences of the United States of America 184 17962413
2013 The evolution of cellular deficiency in GATA2 mutation. Blood 175 24345756
2006 GATA2 functions at multiple steps in hemangioblast development and differentiation. Development (Cambridge, England) 139 17166922
2011 The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Critical reviews in oncology/hematology 138 21605981
2006 Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. Molecular endocrinology (Baltimore, Md.) 133 16543408
2017 GATA2 deficiency and related myeloid neoplasms. Seminars in hematology 124 28637621
2012 Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. The Journal of clinical investigation 124 22996665
1995 Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis. The Journal of clinical investigation 113 7738198
2015 GATA2 deficiency. Current opinion in allergy and clinical immunology 107 25397911
2014 GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proceedings of the National Academy of Sciences of the United States of America 101 25489091
1995 Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. The Journal of biological chemistry 101 7876160
2015 The STAT5-GATA2 pathway is critical in basophil and mast cell differentiation and maintenance. Journal of immunology (Baltimore, Md. : 1950) 95 25801432
2014 A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation. International journal of hematology 83 24638828
2008 GATA-2 regulates granulocyte-macrophage progenitor cell function. Blood 79 18840712
2016 The role of GATA2 in lethal prostate cancer aggressiveness. Nature reviews. Urology 78 27872477
2020 Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood 74 32430494
2023 The spectrum of GATA2 deficiency syndrome. Blood 72 36455197
2016 A Gata2-Dependent Transcription Network Regulates Uterine Progesterone Responsiveness and Endometrial Function. Cell reports 71 27783953
2009 Re-expression of GATA2 cooperates with peroxisome proliferator-activated receptor-gamma depletion to revert the adipocyte phenotype. The Journal of biological chemistry 65 19136559
2020 Human GATA2 mutations and hematologic disease: how many paths to pathogenesis? Blood advances 63 32960960
2018 Germline GATA2 Mutation and Bone Marrow Failure. Hematology/oncology clinics of North America 62 30047422
2015 GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC pulmonary medicine 54 26264606
2014 GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 54 24448395
2017 Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. Leukemia 53 28642594
2014 Cooperative interaction of Etv2 and Gata2 regulates the development of endothelial and hematopoietic lineages. Developmental biology 51 24583263
2004 Partially overlapping expression of Gata2 and Gata3 during inner ear development. Developmental dynamics : an official publication of the American Association of Anatomists 51 15499560
2019 Single-nucleotide human disease mutation inactivates a blood-regenerative GATA2 enhancer. The Journal of clinical investigation 50 30620726
2016 MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation 49 27780851
2021 GATA2 deficiency syndrome: A decade of discovery. Human mutation 47 34387894
2016 GATA2 regulates dendritic cell differentiation. Blood 47 27259979
2013 GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2. Angiogenesis 47 23892628
2022 ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome. Blood advances 44 34529785
2021 GATA2 regulates mast cell identity and responsiveness to antigenic stimulation by promoting chromatin remodeling at super-enhancers. Nature communications 44 33479210
2017 Heterogeneity of GATA2-related myeloid neoplasms. International journal of hematology 43 28643018
2018 Human leukemia mutations corrupt but do not abrogate GATA-2 function. Proceedings of the National Academy of Sciences of the United States of America 41 30301799
2017 GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis. Blood 41 28630119
2019 GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126. Development (Cambridge, England) 40 31582413
2018 GATA2 Is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition. Stem cell reports 40 29861167
2022 A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer. The Journal of clinical investigation 39 35289315
2021 Pulmonary Manifestations of GATA2 Deficiency. Chest 39 34089740
2020 Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories. The Journal of experimental medicine 39 32736380
2023 Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood advances 38 37406166
2018 MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leukemia research 38 30578959
2021 Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. Journal of clinical immunology 36 33417088
2017 In vivo single cell analysis reveals Gata2 dynamics in cells transitioning to hematopoietic fate. The Journal of experimental medicine 36 29217535
2014 Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia. Leukemia 36 24514424
2022 HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood 33 35286385
2021 Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone marrow transplantation 33 34244664
2016 Functional and molecular characterization of mouse Gata2-independent hematopoietic progenitors. Blood 32 26834239
2022 NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma. EMBO reports 30 36416237
2018 GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells. Blood advances 30 30538114
2017 Skin manifestations among GATA2-deficient patients. The British journal of dermatology 30 28440875
2017 Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. Oncogene 30 29106391
2023 Somatic genetic alterations predict hematological progression in GATA2 deficiency. Haematologica 29 36727400
2023 The role of GATA2 in adult hematopoiesis and cell fate determination. Frontiers in cell and developmental biology 29 38033856
2019 Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms. Blood advances 29 31289032
2011 Transcriptional regulation by GATA1 and GATA2 during erythropoiesis. International journal of hematology 29 21279818
2023 Noncoding variants alter GATA2 expression in rhombomere 4 motor neurons and cause dominant hereditary congenital facial paresis. Nature genetics 28 37386251
2019 GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. Stem cell reports 28 31402335
2022 GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. British journal of haematology 27 35753998
2020 Deletion of a conserved Gata2 enhancer impairs haemogenic endothelium programming and adult Zebrafish haematopoiesis. Communications biology 27 32054973
2021 Tumor suppressor function of Gata2 in acute promyelocytic leukemia. Blood 26 34125173
2007 Cell-cycle-dependent oscillation of GATA2 expression in hematopoietic cells. Blood 26 17255359
2020 Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7. British journal of haematology 25 32770553
2015 Histone methyltransferase Setd8 represses Gata2 expression and regulates erythroid maturation. Molecular and cellular biology 25 25848090
2021 Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. Blood 24 33831168
2004 Pur alpha and Sp8 as opposing regulators of neural gata2 expression. Developmental biology 24 15464585
2020 GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes. Cancers 23 33066218
2018 NR4A1 retards adipocyte differentiation or maturation via enhancing GATA2 and p53 expression. Journal of cellular and molecular medicine 23 30044048
2015 GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway. Medical oncology (Northwood, London, England) 23 25707769
2019 GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner. British journal of haematology 22 31710708
2021 Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages. Blood advances 21 34170284
2020 EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis. Blood advances 21 32330245
2020 GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Scientific reports 21 32493985
2022 LINC00891 regulated by miR-128-3p/GATA2 axis impedes lung cancer cell proliferation, invasion and EMT by inhibiting RhoA pathway. Acta biochimica et biophysica Sinica 20 35538035
2017 GATA2 Deficiency and Epstein-Barr Virus Disease. Frontiers in immunology 20 29375553
2023 Role of the pioneer transcription factor GATA2 in health and disease. Journal of molecular medicine (Berlin, Germany) 18 37624387
2022 A feedback loop between GATA2-AS1 and GATA2 promotes colorectal cancer cell proliferation, invasion, epithelial-mesenchymal transition and stemness via recruiting DDX3X. Journal of translational medicine 18 35752837
2020 GATA2 and Progesterone Receptor Interaction in Endometrial Stromal Cells Undergoing Decidualization. Endocrinology 17 32335672
2013 Control of endothelin-a receptor expression by progesterone is enhanced by synergy with Gata2. Molecular endocrinology (Baltimore, Md.) 17 23592430
2023 A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. Journal of experimental & clinical cancer research : CR 16 37507762
2021 Gata2 heterozygous mutant mice exhibit reduced inflammatory responses and impaired bacterial clearance. iScience 16 34471858
2019 A MYC target long non-coding RNA GATA2-AS1 regulates non-small cell lung cancer growth. Neoplasma 16 31607132
2019 Quantitative and qualitative impairments in GATA2 and myeloid neoplasms. IUBMB life 16 31675473
2017 Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget 16 28038451
2009 GATA2-dependent and region-specific regulation of Gata2 transcription in the mouse midbrain. Genes to cells : devoted to molecular & cellular mechanisms 16 19371385
2023 The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. Cancers 15 36900380
2020 A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency. Scientific reports 15 32433473
2019 GATA2 and PU.1 Collaborate To Activate the Expression of the Mouse Ms4a2 Gene, Encoding FcεRIβ, through Distinct Mechanisms. Molecular and cellular biology 15 31501274
2023 GATA2 mitotic bookmarking is required for definitive haematopoiesis. Nature communications 14 37580379
2021 A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT. Journal of clinical immunology 14 34893945
2019 GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. Cancer science 14 30710465
2019 GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies. IUBMB life 14 31785092
2025 GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia. Blood 13 39841459
2021 Inhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocrine-related cancer 13 34636746
2017 GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy. PloS one 13 28114350
2023 TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression. Nature communications 12 37794021

Missed literature

Know a paper Affinage missed for GATA2? Flag it for the maintainers and the community.

No submissions yet.